Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Terns Pharmaceuticals (TERN) Total Non-Current Liabilities (2020 - 2025)

Terns Pharmaceuticals filings provide 6 years of Total Non-Current Liabilities readings, the most recent being $16.9 million for Q4 2025.

  • Quarterly Total Non-Current Liabilities rose 1.73% to $16.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $16.9 million through Dec 2025, up 1.73% year-over-year, with the annual reading at $16.9 million for FY2025, 1.73% up from the prior year.
  • Total Non-Current Liabilities hit $16.9 million in Q4 2025 for Terns Pharmaceuticals, up from $16.0 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $16.9 million in Q4 2025 and bottomed at $6.0 million in Q2 2021.
  • Average Total Non-Current Liabilities over 5 years is $10.9 million, with a median of $11.3 million recorded in 2024.
  • The largest annual shift saw Total Non-Current Liabilities tumbled 69.71% in 2021 before it soared 109.73% in 2023.
  • Terns Pharmaceuticals' Total Non-Current Liabilities stood at $7.0 million in 2021, then grew by 29.11% to $9.0 million in 2022, then surged by 32.53% to $11.9 million in 2023, then surged by 38.72% to $16.6 million in 2024, then grew by 1.73% to $16.9 million in 2025.
  • Per Business Quant, the three most recent readings for TERN's Total Non-Current Liabilities are $16.9 million (Q4 2025), $16.0 million (Q3 2025), and $13.6 million (Q2 2025).